safety of ponatinib in chronic-phase chronic myeloid leukemia (cml) patients
Published 7 years ago • 388 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
1:37
optic: ponatinib in chronic-phase cml
-
4:19
optic: ponatinib in resistant chronic-phase cml
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
1:17
ponatinib versus ascimininib in the third-line treatment of cml
-
1:08
managing drug resistance in cp-cml with ponatinib and asciminib
-
0:44
the recent fda approval of ponatinib for ph all following success in the phallcon trial
-
0:48
b-cell receptor signaling proteins as biomarkers of progression in cll
-
1:44
flowsaver blood return system
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
8:57
outcomes of sct in t-all and t-lbl
-
1:35
long-term follow-up from the oiti trial: ponatinib in patients with cml in italy
-
1:43
dosing strategy of ponatinib in cp-cml: insights from the optic trial
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
1:57
post-hoc analysis of optic: patient responses to ponatinib by t315i mutational status
-
0:58
improving the long-term safety of cll treatment
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
1:32
phase ii efficacy and safety results of ruxolitinib for patients with symptomatic cmml
-
1:29
what are the predictors of ponatinib treatment response?
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies